130 related articles for article (PubMed ID: 11932300)
1. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804.
Lombardo F; Baudin E; Chiefari E; Arturi F; Bardet S; Caillou B; Conte C; Dallapiccola B; Giuffrida D; Bidart JM; Schlumberger M; Filetti S
J Clin Endocrinol Metab; 2002 Apr; 87(4):1674-80. PubMed ID: 11932300
[TBL] [Abstract][Full Text] [Related]
2. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
3. Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia.
Colombo-Benkmann M; Brämswig J; Höppner W; Gellner R; Hengst K; Böcker W; Senninger N
World J Surg; 2002 Oct; 26(10):1286-90. PubMed ID: 12205548
[TBL] [Abstract][Full Text] [Related]
4. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.
Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK
Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662
[TBL] [Abstract][Full Text] [Related]
5. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.
Niccoli-Sire P; Murat A; Rohmer V; Franc S; Chabrier G; Baldet L; Maes B; Savagner F; Giraud S; Bezieau S; Kottler ML; Morange S; Conte-Devolx B;
J Clin Endocrinol Metab; 2001 Aug; 86(8):3746-53. PubMed ID: 11502806
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
[TBL] [Abstract][Full Text] [Related]
7. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
[TBL] [Abstract][Full Text] [Related]
8. A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.
Miyauchi A; Egawa S; Futami H; Kuma K; Obara T; Yamaguchi K
Jpn J Cancer Res; 1997 Jun; 88(6):527-31. PubMed ID: 9263528
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
[TBL] [Abstract][Full Text] [Related]
10. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
11. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
Da Silva AM; Maciel RM; Da Silva MR; Toledo SR; De Carvalho MB; Cerutti JM
J Clin Endocrinol Metab; 2003 Nov; 88(11):5438-43. PubMed ID: 14602786
[TBL] [Abstract][Full Text] [Related]
12. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma].
Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799
[TBL] [Abstract][Full Text] [Related]
13. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation.
Gimm O; Neuberg DS; Marsh DJ; Dahia PL; Hoang-Vu C; Raue F; Hinze R; Dralle H; Eng C
Oncogene; 1999 Feb; 18(6):1369-73. PubMed ID: 10022819
[TBL] [Abstract][Full Text] [Related]
14. [Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers].
Belli S; Storani ME; Dourisboure RJ; Podestá EJ; Solano AR
Medicina (B Aires); 2003; 63(1):41-5. PubMed ID: 12673960
[TBL] [Abstract][Full Text] [Related]
15. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
[TBL] [Abstract][Full Text] [Related]
16. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
17. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome?
Hansen HS; Torring H; Godballe C; Jäger AC; Nielsen FC
Cancer; 2000 Aug; 89(4):863-7. PubMed ID: 10951350
[TBL] [Abstract][Full Text] [Related]
18. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
Fink M; Weinhüsel A; Niederle B; Haas OA
Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
[TBL] [Abstract][Full Text] [Related]
19. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
Kitamura Y; Goodfellow PJ; Shimizu K; Nagahama M; Ito K; Kitagawa W; Akasu H; Takami H; Tanaka S; Wells SA
Oncogene; 1997 Jun; 14(25):3103-6. PubMed ID: 9223675
[TBL] [Abstract][Full Text] [Related]
20. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
